Induction of Protective B Cell Responses to Human Immunodeficiency Virus
The rapid mutation and subsequent tremendous antigenic variation of HIV at the population and individual patient level, coupled with its destruction of CD4 T cells makes it a difficult target for protective vaccine responses. Our laboratory has described key mechanistic features of the B cell response to HIV Envelope among HIV-infected patients, and seeks to develop strategies utilizing diverse animal models for qualitatively tuning the B cell response by vaccination to establish protection from infection. This work includes characterization of the humoral response in high risk populations including injection drug users and men who have sex with men, to ensure sufficient vaccine mediated protection will be achievable in the most vulnerable populations. Through the Rochester Victory Alliance and the HIV Vaccine Trials Network the Kobie Lab conducts mechanistic evaluation of HIV vaccines currently in clinical trials.
« back to all projects